NI201400107A - Compuestos de heterociclilo como inhibidores de mek - Google Patents

Compuestos de heterociclilo como inhibidores de mek

Info

Publication number
NI201400107A
NI201400107A NI201400107A NI201400107A NI201400107A NI 201400107 A NI201400107 A NI 201400107A NI 201400107 A NI201400107 A NI 201400107A NI 201400107 A NI201400107 A NI 201400107A NI 201400107 A NI201400107 A NI 201400107A
Authority
NI
Nicaragua
Prior art keywords
compounds
mek inhibitors
heterocyclyl compounds
formula
present
Prior art date
Application number
NI201400107A
Other languages
English (en)
Inventor
Dave Bhavesh
Kumar Banerjee Rakesh
Phukan Samiron
Datta Khoje Abhijit
Hangarge Rajkumar
Sambhaji Jadhav Jitendra
P Palle Venkata
Kumar Kamboj Rajender
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201400107(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of NI201400107A publication Critical patent/NI201400107A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)

Abstract

La presente invención se relaciona con compuestos de heteroarilo como inhibidores de MEK. Estos compuestos incluyen compuestos de heteroarilo de Fórmula (I), sus sales farmacéuticamente aceptables, combinaciones con composiciones de medicamentos y farmacéuticas adecuadas de los mismos. La presente divulgación también incluye procesos para la preparación de los compuestos y su uso en métodos de tratamiento. Los compuestos tal como se divulgan en la presente son de la Fórmula (I) que figura a continuación.
NI201400107A 2012-03-14 2014-09-11 Compuestos de heterociclilo como inhibidores de mek NI201400107A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14

Publications (1)

Publication Number Publication Date
NI201400107A true NI201400107A (es) 2014-11-26

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
NI201400108A NI201400108A (es) 2012-03-14 2014-09-11 Compuestos de heterociclilo
NI201400107A NI201400107A (es) 2012-03-14 2014-09-11 Compuestos de heterociclilo como inhibidores de mek

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NI201400108A NI201400108A (es) 2012-03-14 2014-09-11 Compuestos de heterociclilo

Country Status (36)

Country Link
US (5) US9428499B2 (es)
EP (2) EP2834237B1 (es)
JP (3) JP6093384B2 (es)
KR (4) KR20140138911A (es)
CN (4) CN104271577A (es)
AP (2) AP3859A (es)
AU (4) AU2013234009B2 (es)
BR (1) BR112014022713B1 (es)
CA (2) CA2865164C (es)
CL (2) CL2014002412A1 (es)
CO (2) CO7170131A2 (es)
CR (2) CR20140464A (es)
CU (2) CU24335B1 (es)
DK (2) DK2834237T3 (es)
DO (2) DOP2014000203A (es)
EA (2) EA029768B1 (es)
ES (2) ES2684517T3 (es)
GE (2) GEP201706774B (es)
GT (2) GT201400196A (es)
HK (2) HK1202538A1 (es)
IL (2) IL234560A (es)
IN (2) IN2014MN01755A (es)
MA (2) MA37405A1 (es)
MX (3) MX355474B (es)
MY (2) MY175950A (es)
NI (2) NI201400108A (es)
NZ (2) NZ629442A (es)
PE (2) PE20141974A1 (es)
PH (2) PH12014502040A1 (es)
PL (1) PL2834237T3 (es)
SG (2) SG11201405007QA (es)
TN (2) TN2014000356A1 (es)
TR (1) TR201811976T4 (es)
UA (2) UA114907C2 (es)
WO (2) WO2013136249A1 (es)
ZA (1) ZA201406186B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
SG11201405007QA (en) 2012-03-14 2014-10-30 Lupin Ltd Heterocyclyl compounds
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
JP6403172B2 (ja) 2013-10-25 2018-10-10 シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20210307A (es) 2017-12-21 2021-07-27 Boehringer Ingelheim Int NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312)
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
KR20220024191A (ko) 2019-06-19 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 항암제 조합 요법
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MX2022001328A (es) * 2019-07-30 2022-05-20 Edvince Ab Inhibidor de proteina quinasa quinasa activada por mitogeno (mek) para el tratamiento de apoplejia.
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11945812B2 (en) 2020-06-02 2024-04-02 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
JP2024514879A (ja) * 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2022402390A1 (en) 2021-12-01 2024-05-30 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099608A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DK1689233T3 (da) 2003-11-19 2012-10-15 Array Biopharma Inc Bicykliske inhibitorer af MEK
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CA2761108A1 (en) 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors
SG11201405007QA (en) * 2012-03-14 2014-10-30 Lupin Ltd Heterocyclyl compounds

Also Published As

Publication number Publication date
CA2865167C (en) 2019-08-06
KR20140138911A (ko) 2014-12-04
KR102240101B1 (ko) 2021-04-14
US9428499B2 (en) 2016-08-30
EP2834236A1 (en) 2015-02-11
CL2014002412A1 (es) 2015-03-06
PH12014502040B1 (en) 2014-11-24
AP2014008009A0 (en) 2014-10-31
BR112014022713B1 (pt) 2021-09-08
EA029768B1 (ru) 2018-05-31
MX355526B (es) 2018-04-20
ES2741896T3 (es) 2020-02-12
CN108383836A (zh) 2018-08-10
AU2017200493A1 (en) 2017-02-16
US9827247B2 (en) 2017-11-28
GT201400196A (es) 2017-09-28
KR20140138910A (ko) 2014-12-04
CO7170131A2 (es) 2015-01-28
PH12014502040A1 (en) 2014-11-24
MX366426B (es) 2019-07-08
JP2018115215A (ja) 2018-07-26
SG11201405007QA (en) 2014-10-30
AP3834A (en) 2016-09-30
AU2017200493B2 (en) 2018-03-29
MA37405A1 (fr) 2016-03-31
MX355474B (es) 2018-04-16
UA114906C2 (uk) 2017-08-28
JP2015514056A (ja) 2015-05-18
CL2014002411A1 (es) 2015-04-06
US20150133424A1 (en) 2015-05-14
MY174188A (en) 2020-03-12
DOP2014000203A (es) 2015-02-15
NZ629432A (en) 2017-01-27
BR112014022713A2 (es) 2017-06-20
DK2834236T3 (da) 2019-08-26
PH12014502041B1 (en) 2014-11-24
CN104203947A (zh) 2014-12-10
TR201811976T4 (tr) 2018-09-21
CN108383836B (zh) 2021-11-12
AP3859A (en) 2016-10-31
MX2014010928A (es) 2015-04-10
EP2834237B1 (en) 2018-06-06
CO7160029A2 (es) 2015-01-15
AU2013234014A1 (en) 2014-09-25
SG11201405006PA (en) 2014-10-30
HK1206020A1 (en) 2015-12-31
CA2865164A1 (en) 2013-09-19
AU2013234009B2 (en) 2016-10-27
EA028232B1 (ru) 2017-10-31
MA37400A1 (fr) 2016-05-31
PL2834237T3 (pl) 2018-11-30
IL234560A (en) 2017-06-29
NZ629442A (en) 2016-12-23
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
EP2834236B1 (en) 2019-05-22
EP2834237A1 (en) 2015-02-11
CU20140110A7 (es) 2014-11-27
AP2014008008A0 (en) 2014-10-31
GEP201706671B (en) 2017-05-25
CA2865167A1 (en) 2013-09-19
JP6630771B2 (ja) 2020-01-15
KR102241111B1 (ko) 2021-04-15
NI201400108A (es) 2014-11-28
KR20190100472A (ko) 2019-08-28
AU2013234014B2 (en) 2017-02-02
UA114907C2 (uk) 2017-08-28
DK2834237T3 (en) 2018-08-27
US9969731B2 (en) 2018-05-15
GEP201706774B (en) 2017-11-27
CU24272B1 (es) 2017-08-08
CR20140464A (es) 2014-11-28
TN2014000357A1 (en) 2015-12-21
WO2013136254A1 (en) 2013-09-19
JP6431770B2 (ja) 2018-11-28
US9555035B2 (en) 2017-01-31
IL234559A (en) 2017-06-29
AU2013234009A1 (en) 2014-09-25
US20170112840A1 (en) 2017-04-27
JP6093384B2 (ja) 2017-03-08
WO2013136249A1 (en) 2013-09-19
US20160331753A1 (en) 2016-11-17
JP2015509975A (ja) 2015-04-02
MX2014010925A (es) 2015-04-10
PE20141974A1 (es) 2014-12-12
ZA201406186B (en) 2016-06-29
CR20140463A (es) 2014-11-28
CN107698585A (zh) 2018-02-16
CU24335B1 (es) 2018-04-03
CN104271577A (zh) 2015-01-07
US9573944B2 (en) 2017-02-21
PH12014502041A1 (en) 2014-11-24
US20150299186A1 (en) 2015-10-22
DOP2014000204A (es) 2015-02-15
CU20140109A7 (es) 2014-11-27
EA201491672A1 (ru) 2014-12-30
GT201400195A (es) 2017-11-09
MA37400B1 (fr) 2019-11-29
KR20190073597A (ko) 2019-06-26
EA201491671A1 (ru) 2014-12-30
HK1202538A1 (en) 2015-10-02
PE20141973A1 (es) 2014-12-12
CA2865164C (en) 2021-06-08
ES2684517T3 (es) 2018-10-03
IN2014MN01755A (es) 2015-07-03
AU2018202568A1 (en) 2018-05-10
IN2014MN01754A (es) 2015-07-03
AU2018202568B2 (en) 2019-05-09
US20170101408A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
ECSP19011216A (es) Inhibidores de piridopyrimdinona cdk2/4/6
ECSP14013215A (es) Compuestos novedosos
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
CR20150045A (es) Inhibidores de hepatitis c
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
ECSP16074478A (es) Compuestos novedosos
NI201600014A (es) Compuestos y composiciones como inhibidores de la mek.
ECSP17069696A (es) Compuestos novedosos
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
NI201500096A (es) Compuesto químicos
ECSP15013883A (es) Benzamidas
UY33490A (es) Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos.
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
EA201600394A1 (ru) Трициклические соединения пиперидина
CU20160157A7 (es) Derivados de diheterociclo enlazado a cicloalquilo
ECSP16074482A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
EA201590656A1 (ru) Азаиндолины
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ